Navigation Links
Treating safety research like other clinical studies slows progress
Date:5/13/2008

Progress in patient safety research could slow to a crawl unless regulators work out a host of ethical issues, Johns Hopkins researchers assert in an upcoming opinion piece.

We cant apply a clinical paradigm to patient safety research. It just isnt the right fit, says Nancy Kass, Sc.D., deputy director for public health at the Johns Hopkins Berman Institute of Bioethics and an author of the article.

The piece, published in the June issue of The Joint Commission Journal on Quality and Patient Safety, was sparked by a 2006 study led by Peter Pronovost, M.D., Ph.D., professor of anesthesiology, critical care medicine, and surgery at the Johns Hopkins University School of Medicine. In the study, Pronovost, an expert on patient safety, implemented a checklist in intensive care units (ICUs) at 67 Michigan hospitals aimed at preventing bloodstream infections whenever doctors insert catheters.

The results were markedly positive: Bloodstream infections from catheters fell by two-thirds, and on average, infection rates in the ICUs went from 4 percent to zero. Over the course of the study, the program saved more than 1,500 lives and nearly $200 million.

Shortly after the studys results were published, however, an anonymous complaint led to a federal reexamination of the ethical oversight of the study. As in most human research, Pronovosts study had been reviewed by an institutional review board (IRB)an internal group required at most research institutions to use federal regulations to make sure research studies protect the welfare of human subjects.

Because Pronovosts study enforced safety measures already known to be effective, and because no data were ever collected from patients by name, the Johns Hopkins IRB classified Pronovosts study as exempt from further IRB review. This designation meant that informed consent was not necessary from the ICU patients and that IRB review from each of the 67 Michigan hospitals that part
'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
3. Treating diabetes during pregnancy can break link to childhood obesity
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Treating depression may improve recovery of heart rate variability following coronary syndromes
8. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
9. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
10. Stem cells show promise for treating Huntingtons disease
11. Treating obstructive sleep apnea, preventing heart attacks and strokes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Robert J. Reilly, Joins Aethon Team, PITTSBURGH,...aethon.com ), the leading developer of mobile robo...nounced that Robert J. Reilly has,joined the compa...icer., Reilly, who was most recently Vice Preside...pecialty Pharmacy Division, brings more than 30,ye...
(Date:7/25/2008)...ce to be presented at Fenway Park ... /PRNewswire/ -- CVS/pharmacy announced today,that...llion in just 21 days,through its annual in-store ... seventh year of the annual fundraising effort whi...ALS research. This year,s fundraiser took,place in...
(Date:7/25/2008)...ng to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl...Now, researchers have some science to back up diet...: Most people do eat more on the weekend, even whe...ulgences can wreak havoc on weight control, either...
(Date:7/25/2008)...re an Olympian, Professional Athlete, Elite Amateu...ed to Know about Hydration to Boost Sports Perform... Marina del Rey, Calif. (V...are heading to Beijing following years of intense ...of capturing an Olympic medal and securing their p...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...tching some rays has been shown to boost vitamin D... the risk of disease. Higher sun exposure during c...a reduced risk of multiple sclerosis, according to...ucted a study in Tasmania, which is located at hig...
...w research shows women who allow only short interv...d risk for developing complications. Researchers i...en birth twice between 1992 and 1998. Results of t...t births are much more likely to become pregnant a...
Indians Stay Away from Coke, Pepsi After Toxin Scare
...ctors usually prescribe antibiotics for problems l...e drugs, especially penicillin, may also protect a...ia prevent a problem that involves the blockage of...s often occur when cholesterol plaques in blood ve...
Other Medicine News:
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: